Akari Therap
AKTX----
Akari Therap (AKTX)
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Akari Therap Analyst Rating
View MoreForecast & Rating
Jul 20, 2026Price forecast
$28.39226.32%
Forecast & RatingBuy
2analysts
- Strong buy50.00%
- Buy50.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 22 at 07:40 AM
Akari Therapeutics enters strategic ADC payload research collaboration with Whitehawk Therapeutics
- GlobeNewswire · Jul 22 at 07:40 AM
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity
- benzinga_article · Jul 21 at 07:05 AM
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- StockTitan · Jul 20 at 10:05 PM
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics | AKTX Stock News
- benzinga_article · Jul 7 at 12:05 PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
- StockTitan · Jul 6 at 11:55 PM
Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso,., to Scientific Advisory Board | AKTX Stock News
